Analysts Set Stoke Therapeutics, Inc. (NASDAQ:STOK) Target Price at $20.83

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) has been assigned an average recommendation of "Buy" from the nine analysts that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $20.83.

A number of equities research analysts have issued reports on STOK shares. Leerink Partners started coverage on Stoke Therapeutics in a research note on Monday, October 14th. They issued an "outperform" rating and a $18.00 price target for the company. HC Wainwright reissued a "buy" rating and issued a $35.00 price target on shares of Stoke Therapeutics in a report on Wednesday, September 11th. Needham & Company LLC reaffirmed a "buy" rating and set a $22.00 price objective on shares of Stoke Therapeutics in a report on Thursday, August 8th. Leerink Partnrs raised shares of Stoke Therapeutics to a "strong-buy" rating in a report on Friday, October 11th. Finally, Wedbush restated an "outperform" rating and set a $17.00 target price on shares of Stoke Therapeutics in a research report on Thursday, July 11th.

Stoke Therapeutics Stock Down 3.7 %

NASDAQ:STOK traded down $0.46 during mid-day trading on Wednesday, hitting $12.06. 174,121 shares of the company traded hands, compared to its average volume of 781,887. The stock's fifty day moving average price is $13.58 and its 200-day moving average price is $13.70. The firm has a market cap of $634.96 million, a price-to-earnings ratio of -5.53 and a beta of 0.97. Stoke Therapeutics has a one year low of $3.35 and a one year high of $17.58.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last released its earnings results on Wednesday, August 7th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.11. The company had revenue of $4.83 million during the quarter, compared to analyst estimates of $3.33 million. Stoke Therapeutics had a negative net margin of 683.35% and a negative return on equity of 57.89%. Equities analysts predict that Stoke Therapeutics will post -2.1 EPS for the current year.

Insider Transactions at Stoke Therapeutics

In related news, major shareholder Skorpios Trust sold 1,937,500 shares of the firm's stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $14.05, for a total value of $27,221,875.00. Following the completion of the sale, the insider now directly owns 8,906,181 shares in the company, valued at $125,131,843.05. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 11.30% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the business. Assenagon Asset Management S.A. purchased a new position in Stoke Therapeutics during the 2nd quarter valued at $19,835,000. SG Americas Securities LLC increased its stake in Stoke Therapeutics by 610.3% in the 2nd quarter. SG Americas Securities LLC now owns 68,601 shares of the company's stock worth $927,000 after buying an additional 58,943 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new stake in Stoke Therapeutics during the 1st quarter valued at about $1,224,000. Vanguard Group Inc. boosted its position in Stoke Therapeutics by 4.1% in the 1st quarter. Vanguard Group Inc. now owns 1,715,554 shares of the company's stock valued at $23,160,000 after buying an additional 67,052 shares during the period. Finally, Healthcare of Ontario Pension Plan Trust Fund boosted its position in Stoke Therapeutics by 426.1% in the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,387,200 shares of the company's stock valued at $18,741,000 after buying an additional 1,123,500 shares during the period.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.